Cantor Fitzgerald Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $100
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has maintained an Overweight rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but lowered the price target from $120 to $100.
November 02, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Biomarin Pharmaceutical's price target has been lowered from $120 to $100 by Cantor Fitzgerald, though the Overweight rating is maintained.
The lowering of the price target by Cantor Fitzgerald could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term. However, the maintained Overweight rating indicates that the analyst still sees potential in the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100